25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

BIO (Biotest) Stock Analysis
Buy, Hold or Sell?

Let's analyze Biotest together

I guess you are interested in Biotest Aktiengesellschaft. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Biotest’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Biotest’s Price Targets

I'm going to help you getting a better view of Biotest Aktiengesellschaft. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Biotest Aktiengesellschaft

I send you an email if I find something interesting about Biotest Aktiengesellschaft.

1. Quick Overview

1.1. Quick analysis of Biotest (30 sec.)










1.2. What can you expect buying and holding a share of Biotest? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€12.88
Expected worth in 1 year
€12.42
How sure are you?
36.4%

+ What do you gain per year?

Total Gains per Share
€-0.46
Return On Investment
-1.1%

For what price can you sell your share?

Current Price per Share
€43.40
Expected price per share
€38.96 - €42.16
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Biotest (5 min.)




Live pricePrice per Share (EOD)
€43.40
Intrinsic Value Per Share
€-101.54 - €-121.78
Total Value Per Share
€-88.66 - €-108.90

2.2. Growth of Biotest (5 min.)




Is Biotest growing?

Current yearPrevious yearGrowGrow %
How rich?$594.9m$542.8m$71m11.6%

How much money is Biotest making?

Current yearPrevious yearGrowGrow %
Making money-$7.1m$51.6m-$58.7m-822.0%
Net Profit Margin-4.7%21.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Biotest (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Biotest?

Welcome investor! Biotest's management wants to use your money to grow the business. In return you get a share of Biotest.

First you should know what it really means to hold a share of Biotest. And how you can make/lose money.

Speculation

The Price per Share of Biotest is €43.40. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Biotest.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Biotest, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €12.88. Based on the TTM, the Book Value Change Per Share is €-0.12 per quarter. Based on the YOY, the Book Value Change Per Share is €1.12 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Biotest.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 β‚¬% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share€% of Price per Share
Usd Eps-0.63-1.5%-0.18-0.4%1.303.0%0.260.6%0.020.1%0.000.0%
Usd Book Value Change Per Share-0.62-1.4%-0.13-0.3%1.303.0%0.330.8%0.060.1%0.681.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.62-1.4%-0.13-0.3%1.303.0%0.330.8%0.060.1%0.681.6%
Usd Price Per Share46.93-47.63-49.44-48.78-44.83-37.60-
Price to Earnings Ratio-18.58--34.17-12.17-0.35-21.09-12.00-
Price-to-Total Gains Ratio-75.39-109.84-48.65-33.34--54.95--52.91-
Price to Book Ratio3.12-3.07-3.66-3.81-3.56-2.98-
Price-to-Total Gains Ratio-75.39-109.84-48.65-33.34--54.95--52.91-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share50.66516
Number of shares19
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.130.06
Usd Total Gains Per Share-0.130.06
Gains per Quarter (19 shares)-2.561.22
Gains per Year (19 shares)-10.264.87
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-10-2005-5
20-21-300100
30-31-400155
40-41-5001910
50-51-6002415
60-62-7002920
70-72-8003425
80-82-9003930
90-92-10004435
100-103-11004940

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%6.06.00.050.0%7.013.00.035.0%7.015.00.031.8%7.015.00.031.8%
Book Value Change Per Share2.02.00.050.0%7.05.00.058.3%7.013.00.035.0%8.014.00.036.4%8.014.00.036.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.022.00.0%0.00.022.00.0%
Total Gains per Share2.02.00.050.0%7.05.00.058.3%7.013.00.035.0%8.014.00.036.4%8.014.00.036.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Biotest Aktiengesellschaft compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.533-0.116-78%1.117-148%0.283-288%0.055-1072%0.585-191%
Book Value Per Share--12.87813.291-3%11.752+10%11.348+13%11.058+16%9.800+31%
Current Ratio--4.9263.745+32%3.514+40%3.935+25%4.364+13%4.269+15%
Debt To Asset Ratio--0.6400.622+3%0.658-3%0.656-2%0.645-1%0.626+2%
Debt To Equity Ratio--1.7801.650+8%1.938-8%1.933-8%1.838-3%1.717+4%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--683872370.400747190241.600-8%785575992.200-13%805085502.733-15%727446614.060-6%670277805.591+2%
Eps---0.541-0.155-71%1.118-148%0.222-344%0.021-2710%0.004-14179%
Ev To Sales Ratio--1.3771.210+14%1.026+34%1.325+4%1.283+7%1.186+16%
Free Cash Flow Per Share---1.468-0.090-94%-0.066-96%-0.320-78%-0.189-87%-0.186-87%
Free Cash Flow To Equity Per Share---1.468-0.090-94%-0.066-96%-0.320-78%-0.189-87%-0.186-87%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---121.779----------
Intrinsic Value_10Y_min---101.535----------
Intrinsic Value_1Y_max---2.864----------
Intrinsic Value_1Y_min---2.808----------
Intrinsic Value_3Y_max---15.723----------
Intrinsic Value_3Y_min---14.867----------
Intrinsic Value_5Y_max---37.162----------
Intrinsic Value_5Y_min---33.881----------
Market Cap--1590772370.4001614515241.600-1%1675850992.200-5%1653427169.400-4%1519741614.060+5%1274596468.920+25%
Net Profit Margin---0.172-0.047-73%0.218-179%0.024-832%-0.021-88%-0.023-86%
Operating Margin----0%-0%-0%-0.0060%-0.0020%
Operating Ratio--2.0641.774+16%1.355+52%1.645+25%1.727+19%1.726+20%
Pb Ratio3.370+7%3.1223.071+2%3.664-15%3.809-18%3.564-12%2.976+5%
Pe Ratio-20.063-8%-18.584-34.172+84%12.167-253%0.353-5364%21.085-188%11.999-255%
Price Per Share43.400+7%40.20040.800-1%42.350-5%41.783-4%38.405+5%32.210+25%
Price To Free Cash Flow Ratio-7.390-8%-6.8457.185-195%9.543-172%0.217-3259%5.603-222%0.195-3605%
Price To Total Gains Ratio-81.393-8%-75.392109.836-169%48.646-255%33.340-326%-54.947-27%-52.906-30%
Quick Ratio--1.0820.791+37%0.948+14%0.929+16%1.024+6%1.025+5%
Return On Assets---0.015-0.004-71%0.033-146%0.006-356%0.000-97%-0.001-94%
Return On Equity---0.042-0.012-71%0.095-144%0.017-354%-0.001-98%-0.002-95%
Total Gains Per Share---0.533-0.116-78%1.117-148%0.283-288%0.055-1072%0.585-191%
Usd Book Value--594907040.000613964845.000-3%542899370.000+10%524220970.000+13%510825055.000+16%521893174.400+14%
Usd Book Value Change Per Share---0.622-0.135-78%1.304-148%0.331-288%0.064-1072%0.683-191%
Usd Book Value Per Share--15.03415.515-3%13.719+10%13.247+13%12.909+16%11.440+31%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--798352605.205872269888.044-8%917081413.294-13%939856815.891-15%849221177.254-6%782482310.247+2%
Usd Eps---0.631-0.181-71%1.305-148%0.259-344%0.024-2710%0.004-14179%
Usd Free Cash Flow---67825940.000-4173455.000-94%-3035240.000-96%-14767610.000-78%-8714641.000-87%-9031006.400-87%
Usd Free Cash Flow Per Share---1.714-0.105-94%-0.077-96%-0.373-78%-0.220-87%-0.217-87%
Usd Free Cash Flow To Equity Per Share---1.714-0.105-94%-0.077-96%-0.373-78%-0.220-87%-0.217-87%
Usd Market Cap--1857067665.2051884785093.044-1%1956388448.294-5%1930210877.558-4%1774146360.254+5%1487963917.817+25%
Usd Price Per Share50.665+7%46.92947.630-1%49.439-5%48.778-4%44.834+5%37.602+25%
Usd Profit---24982360.000-7150325.000-71%51628265.000-148%10234206.667-344%957268.000-2710%42026.400-59544%
Usd Revenue--144991080.000185383120.000-22%228372625.000-37%188252978.333-23%172372447.000-16%162030450.400-11%
Usd Total Gains Per Share---0.622-0.135-78%1.304-148%0.331-288%0.064-1072%0.683-191%
 EOD+3 -3MRQTTM+5 -30YOY+12 -233Y+12 -235Y+14 -2110Y+13 -22

3.3 Fundamental Score

Let's check the fundamental score of Biotest Aktiengesellschaft based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-20.063
Price to Book Ratio (EOD)Between0-13.370
Net Profit Margin (MRQ)Greater than0-0.172
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.082
Current Ratio (MRQ)Greater than14.926
Debt to Asset Ratio (MRQ)Less than10.640
Debt to Equity Ratio (MRQ)Less than11.780
Return on Equity (MRQ)Greater than0.15-0.042
Return on Assets (MRQ)Greater than0.05-0.015
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Biotest Aktiengesellschaft based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose43.400
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Biotest Aktiengesellschaft

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, including neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B immunoglobulins. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols Biotest Holdings GmbH.

Fundamental data was last updated by Penke on 2025-07-09 06:46:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Biotest earns for each €1 of revenue.

  • Above 10% is considered healthy but always compareΒ Biotest to theΒ  industry mean.
  • A Net Profit Margin of -17.2%Β means thatΒ €-0.17 for each €1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Biotest Aktiengesellschaft:

  • The MRQ is -17.2%. The company is making a huge loss. -2
  • The TTM is -4.7%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ-17.2%TTM-4.7%-12.5%
TTM-4.7%YOY21.8%-26.5%
TTM-4.7%5Y-2.1%-2.6%
5Y-2.1%10Y-2.3%+0.2%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Biotest is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Biotest to theΒ  industry mean.
  • -1.5% Return on Assets means thatΒ Biotest generatedΒ €-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Biotest Aktiengesellschaft:

  • The MRQ is -1.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -0.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.5%TTM-0.4%-1.1%
TTM-0.4%YOY3.3%-3.7%
TTM-0.4%5Y0.0%-0.4%
5Y0.0%10Y-0.1%+0.0%
4.3.1.3. Return on Equity

Shows how efficient Biotest is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Biotest to theΒ  industry mean.
  • -4.2% Return on Equity means Biotest generated €-0.04Β for eachΒ €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Biotest Aktiengesellschaft:

  • The MRQ is -4.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -1.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.2%TTM-1.2%-3.0%
TTM-1.2%YOY9.5%-10.7%
TTM-1.2%5Y-0.1%-1.1%
5Y-0.1%10Y-0.2%+0.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Biotest Aktiengesellschaft.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Biotest is operatingΒ .

  • Measures how much profit Biotest makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Biotest to theΒ  industry mean.
  • An Operating Margin of 0.0%Β means the company generated €0.00 Β for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Biotest Aktiengesellschaft:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.6%+0.6%
5Y-0.6%10Y-0.2%-0.4%
4.3.2.2. Operating Ratio

Measures how efficient Biotest is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ  industry mean).
  • An Operation Ratio of 2.06 means that the operating costs are €2.06 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 2.064. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.774. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.064TTM1.774+0.289
TTM1.774YOY1.355+0.420
TTM1.7745Y1.727+0.047
5Y1.72710Y1.726+0.002
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Biotest Aktiengesellschaft.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Biotest is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ  industry mean).
  • A Current Ratio of 4.93Β means the company has €4.93 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 4.926. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.745. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.926TTM3.745+1.182
TTM3.745YOY3.514+0.231
TTM3.7455Y4.364-0.619
5Y4.36410Y4.269+0.095
4.4.3.2. Quick Ratio

Measures if Biotest is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Biotest to theΒ  industry mean.
  • A Quick Ratio of 1.08Β means the company can pay off €1.08 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 1.082. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 0.791. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ1.082TTM0.791+0.291
TTM0.791YOY0.948-0.157
TTM0.7915Y1.024-0.234
5Y1.02410Y1.025-0.001
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Biotest Aktiengesellschaft.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of BiotestΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Biotest to industry mean.
  • A Debt to Asset Ratio of 0.64Β means that Biotest assets areΒ financed with 64.0% credit (debt) and the remaining percentage (100% - 64.0%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 0.640. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.622. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.640TTM0.622+0.018
TTM0.622YOY0.658-0.036
TTM0.6225Y0.645-0.023
5Y0.64510Y0.626+0.019
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Biotest is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Biotest to theΒ  industry mean.
  • A Debt to Equity ratio of 178.0% means that company has €1.78 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 1.780. The company is just able to pay all its debts with equity.
  • The TTM is 1.650. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.780TTM1.650+0.129
TTM1.650YOY1.938-0.288
TTM1.6505Y1.838-0.188
5Y1.83810Y1.717+0.121
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every €1 in earnings Biotest generates.

  • Above 15 is considered overpriced butΒ always compareΒ Biotest to theΒ  industry mean.
  • A PE ratio of -18.58 means the investor is paying €-18.58Β for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Biotest Aktiengesellschaft:

  • The EOD is -20.063. Based on the earnings, the company is expensive. -2
  • The MRQ is -18.584. Based on the earnings, the company is expensive. -2
  • The TTM is -34.172. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-20.063MRQ-18.584-1.479
MRQ-18.584TTM-34.172+15.588
TTM-34.172YOY12.167-46.339
TTM-34.1725Y21.085-55.257
5Y21.08510Y11.999+9.086
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Biotest Aktiengesellschaft:

  • The EOD is -7.390. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.845. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 7.185. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-7.390MRQ-6.845-0.545
MRQ-6.845TTM7.185-14.030
TTM7.185YOY9.543-2.358
TTM7.1855Y5.603+1.582
5Y5.60310Y0.195+5.407
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Biotest is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to industry mean).
  • A PB ratio of 3.12 means the investor is paying €3.12Β for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Biotest Aktiengesellschaft:

  • The EOD is 3.370. Based on the equity, the company is fair priced.
  • The MRQ is 3.122. Based on the equity, the company is fair priced.
  • The TTM is 3.071. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.370MRQ3.122+0.248
MRQ3.122TTM3.071+0.051
TTM3.071YOY3.664-0.594
TTM3.0715Y3.564-0.494
5Y3.56410Y2.976+0.588
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets1,416,500
Total Liabilities906,900
Total Stockholder Equity509,600
 As reported
Total Liabilities 906,900
Total Stockholder Equity+ 509,600
Total Assets = 1,416,500

Assets

Total Assets1,416,500
Total Current Assets788,700
Long-term Assets627,800
Total Current Assets
Cash And Cash Equivalents 41,800
Short-term Investments 18,000
Net Receivables 155,200
Inventory 523,700
Other Current Assets 8,300
Total Current Assets  (as reported)788,700
Total Current Assets  (calculated)747,000
+/- 41,700
Long-term Assets
Property Plant Equipment 566,800
Long-term Assets Other 200
Long-term Assets  (as reported)627,800
Long-term Assets  (calculated)567,000
+/- 60,800

Liabilities & Shareholders' Equity

Total Current Liabilities160,100
Long-term Liabilities746,800
Total Stockholder Equity509,600
Total Current Liabilities
Accounts payable 83,600
Other Current Liabilities 21,800
Total Current Liabilities  (as reported)160,100
Total Current Liabilities  (calculated)105,400
+/- 54,700
Long-term Liabilities
Long-term Liabilities Other 700
Long-term Liabilities  (as reported)746,800
Long-term Liabilities  (calculated)700
+/- 746,100
Total Stockholder Equity
Retained Earnings 253,300
Total Stockholder Equity (as reported)509,600
Total Stockholder Equity (calculated)253,300
+/- 256,300
Other
Capital Stock39,600
Common Stock Shares Outstanding 39,571
Net Invested Capital 509,600
Net Working Capital 628,600
Property Plant and Equipment Gross 566,800



6.2. Balance Sheets Structured

Currency in EUR. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
1,044,600
1,058,200
1,091,000
1,108,400
1,107,600
1,145,200
1,122,200
1,131,300
1,134,800
1,145,800
1,135,400
1,104,200
1,109,800
1,101,900
1,079,300
1,203,000
1,190,200
1,214,100
1,349,500
1,410,900
1,446,800
1,375,800
1,346,700
1,434,000
1,416,500
1,416,5001,434,0001,346,7001,375,8001,446,8001,410,9001,349,5001,214,1001,190,2001,203,0001,079,3001,101,9001,109,8001,104,2001,135,4001,145,8001,134,8001,131,3001,122,2001,145,2001,107,6001,108,4001,091,0001,058,2001,044,600
   > Total Current Assets 
476,100
488,600
508,500
522,800
525,600
563,900
542,200
556,300
560,600
570,500
556,600
522,200
523,900
522,000
497,500
619,400
597,400
620,700
736,200
756,500
796,200
738,900
704,500
809,500
788,700
788,700809,500704,500738,900796,200756,500736,200620,700597,400619,400497,500522,000523,900522,200556,600570,500560,600556,300542,200563,900525,600522,800508,500488,600476,100
       Cash And Cash Equivalents 
43,400
49,800
65,500
60,800
44,000
63,700
40,200
71,300
55,000
72,000
79,200
104,400
115,300
85,000
53,300
116,600
68,000
58,300
65,400
108,100
84,700
66,300
24,700
107,800
41,800
41,800107,80024,70066,30084,700108,10065,40058,30068,000116,60053,30085,000115,300104,40079,20072,00055,00071,30040,20063,70044,00060,80065,50049,80043,400
       Short-term Investments 
52,500
31,900
34,100
24,900
20,600
31,000
32,800
17,900
13,300
13,100
12,100
13,100
14,800
18,100
23,600
20,000
18,900
12,600
13,400
10,400
14,100
18,400
13,100
11,700
18,000
18,00011,70013,10018,40014,10010,40013,40012,60018,90020,00023,60018,10014,80013,10012,10013,10013,30017,90032,80031,00020,60024,90034,10031,90052,500
       Net Receivables 
94,200
108,400
104,800
107,700
93,300
112,600
108,900
115,800
122,400
115,100
107,400
107,300
86,200
97,200
93,400
124,500
120,400
149,300
210,300
145,200
201,000
131,300
132,100
157,900
155,200
155,200157,900132,100131,300201,000145,200210,300149,300120,400124,50093,40097,20086,200107,300107,400115,100122,400115,800108,900112,60093,300107,700104,800108,40094,200
       Inventory 
236,000
247,000
257,300
280,100
312,400
304,300
306,900
290,100
301,800
303,100
298,100
244,600
255,800
263,200
268,700
293,800
327,600
341,100
373,600
419,100
438,700
472,500
487,600
479,500
523,700
523,700479,500487,600472,500438,700419,100373,600341,100327,600293,800268,700263,200255,800244,600298,100303,100301,800290,100306,900304,300312,400280,100257,300247,000236,000
       Other Current Assets 
12,900
10,100
6,900
1,400
9,600
8,400
9,700
1,200
18,700
13,400
12,100
3,100
18,000
15,400
23,600
3,100
20,400
15,300
29,300
2,700
12,200
10,700
7,300
2,000
8,300
8,3002,0007,30010,70012,2002,70029,30015,30020,4003,10023,60015,40018,0003,10012,10013,40018,7001,2009,7008,4009,6001,4006,90010,10012,900
   > Long-term Assets 
568,500
569,600
582,500
585,600
582,000
581,300
580,000
575,000
574,200
575,300
578,800
582,000
585,900
579,900
581,800
583,600
592,700
593,400
613,300
654,400
650,600
636,900
642,200
624,500
627,800
627,800624,500642,200636,900650,600654,400613,300593,400592,700583,600581,800579,900585,900582,000578,800575,300574,200575,000580,000581,300582,000585,600582,500569,600568,500
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
543,800
547,800
549,600
555,700
573,400
578,400
581,100
575,400
573,900
570,800
566,800
566,800570,800573,900575,400581,100578,400573,400555,700549,600547,800543,80000000000000000
       Goodwill 
0
0
0
7,200
0
0
0
7,100
0
0
0
7,100
0
0
0
7,200
0
0
0
6,000
0
0
0
6,000
0
06,0000006,0000007,2000007,1000007,1000007,200000
       Intangible Assets 
0
0
0
6,600
0
0
0
6,900
0
0
0
4,100
0
0
0
9,200
0
0
0
9,000
0
0
0
10,500
0
010,5000009,0000009,2000004,1000006,9000006,600000
       Long-term Assets Other 
100
569,600
7,700
100
5,600
3,600
3,700
100
300
100
100
400
500
300
500
100
200
200
200
100
100
100
200
100
200
2001002001001001002002002001005003005004001001003001003,7003,6005,6001007,700569,600100
> Total Liabilities 
550,700
562,000
599,300
631,500
641,400
685,900
678,000
689,700
707,100
723,400
723,200
723,800
734,700
743,200
735,500
831,900
839,100
840,600
889,600
912,000
918,900
839,900
819,200
903,300
906,900
906,900903,300819,200839,900918,900912,000889,600840,600839,100831,900735,500743,200734,700723,800723,200723,400707,100689,700678,000685,900641,400631,500599,300562,000550,700
   > Total Current Liabilities 
107,800
415,600
101,100
115,000
123,100
113,800
103,300
105,600
121,100
111,100
103,800
106,400
114,900
122,200
109,600
130,200
129,500
122,800
147,200
385,300
391,200
301,200
277,100
160,100
160,100
160,100160,100277,100301,200391,200385,300147,200122,800129,500130,200109,600122,200114,900106,400103,800111,100121,100105,600103,300113,800123,100115,000101,100415,600107,800
       Short-term Debt 
0
0
0
3,300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000003,300000
       Short Long Term Debt 
0
0
0
3,300
0
0
0
3,500
0
0
0
1,600
0
0
0
4,800
0
0
0
226,800
0
0
0
200
0
0200000226,8000004,8000001,6000003,5000003,300000
       Accounts payable 
50,600
63,300
40,100
52,200
54,700
49,000
37,700
42,000
49,300
43,800
31,500
38,800
38,700
42,200
30,200
51,100
44,700
54,500
53,300
78,100
77,200
69,400
58,100
88,400
83,600
83,60088,40058,10069,40077,20078,10053,30054,50044,70051,10030,20042,20038,70038,80031,50043,80049,30042,00037,70049,00054,70052,20040,10063,30050,600
       Other Current Liabilities 
25,700
28,900
30,400
7,700
33,100
34,700
33,500
5,900
35,400
39,100
39,500
4,300
14,900
18,900
11,900
4,900
21,100
18,300
20,800
5,800
16,500
17,200
12,400
6,900
21,800
21,8006,90012,40017,20016,5005,80020,80018,30021,1004,90011,90018,90014,9004,30039,50039,10035,4005,90033,50034,70033,1007,70030,40028,90025,700
   > Long-term Liabilities 
442,900
146,400
498,200
516,500
518,300
572,100
574,700
584,100
586,000
612,300
619,400
617,400
619,800
621,000
625,900
701,700
709,600
717,800
742,400
526,700
527,700
538,700
542,100
743,200
746,800
746,800743,200542,100538,700527,700526,700742,400717,800709,600701,700625,900621,000619,800617,400619,400612,300586,000584,100574,700572,100518,300516,500498,200146,400442,900
       Capital Lease Obligations Min Short Term Debt
0
0
0
23,400
0
0
0
27,400
0
0
0
26,800
0
0
0
29,000
0
0
0
57,800
0
0
0
58,500
0
058,50000057,80000029,00000026,80000027,40000023,400000
       Long-term Liabilities Other 
100
200
200
300
100
0
0
-600
0
0
0
-1,900
0
0
100
-700
0
0
0
-300
0
0
0
300
700
700300000-300000-70010000-1,900000-60000100300200200100
> Total Stockholder Equity
493,900
496,200
491,700
476,900
466,200
459,300
444,200
441,600
427,700
422,400
412,200
380,400
375,100
358,700
343,800
371,100
351,100
373,500
459,900
498,900
527,900
535,900
527,500
530,700
509,600
509,600530,700527,500535,900527,900498,900459,900373,500351,100371,100343,800358,700375,100380,400412,200422,400427,700441,600444,200459,300466,200476,900491,700496,200493,900
   Common Stock0000000000000000000000000
   Retained Earnings 
52,900
234,800
232,300
217,500
206,800
199,900
184,800
182,200
168,300
163,000
152,800
121,000
115,700
99,300
84,400
111,700
91,700
114,100
200,500
249,800
268,500
276,500
268,100
274,500
253,300
253,300274,500268,100276,500268,500249,800200,500114,10091,700111,70084,40099,300115,700121,000152,800163,000168,300182,200184,800199,900206,800217,500232,300234,80052,900
   Capital Surplus 0000000000000000000000000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 0000000000000000000000000



6.3. Balance Sheets

Currency in EUR. All numbers in thousands.




6.4. Cash Flows

Currency in EUR. All numbers in thousands.




6.5. Income Statements

Currency in EUR. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in EUR. All numbers in thousands.

Gross Profit (+$)
totalRevenue726,200
Cost of Revenue-502,400
Gross Profit223,800223,800
 
Operating Income (+$)
Gross Profit223,800
Operating Expense-640,500
Operating Income85,700-416,700
 
Operating Expense (+$)
Research Development56,800
Selling General Administrative88,300
Selling And Marketing Expenses0
Operating Expense640,500145,100
 
Net Interest Income (+$)
Interest Income2,000
Interest Expense-33,300
Other Finance Cost-1,500
Net Interest Income-32,800
 
Pretax Income (+$)
Operating Income85,700
Net Interest Income-32,800
Other Non-Operating Income Expenses0
Income Before Tax (EBT)46,50085,700
EBIT - interestExpense = -33,300
26,400
59,700
Interest Expense33,300
Earnings Before Interest and Taxes (EBIT)079,800
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax46,500
Tax Provision-20,200
Net Income From Continuing Ops26,40026,300
Net Income26,400
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net032,800
 

Technical Analysis of Biotest
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Biotest. The general trend of Biotest is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Biotest's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Biotest Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Biotest Aktiengesellschaft.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 41.56 < 41.56 < 42.16.

The bearish price targets are: 41.20 > 38.96.

Know someone who trades $BIO? Share this with them.πŸ‘‡

Biotest Aktiengesellschaft Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Biotest Aktiengesellschaft. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Biotest Aktiengesellschaft Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Biotest Aktiengesellschaft.

Biotest Aktiengesellschaft Daily Moving Average Convergence/Divergence (MACD) ChartBiotest Aktiengesellschaft Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Biotest Aktiengesellschaft. The current adx is .

Biotest Aktiengesellschaft Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Biotest Aktiengesellschaft.

Biotest Aktiengesellschaft Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Biotest Aktiengesellschaft.

Biotest Aktiengesellschaft Daily Relative Strength Index (RSI) ChartBiotest Aktiengesellschaft Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Biotest Aktiengesellschaft.

Biotest Aktiengesellschaft Daily Stochastic Oscillator ChartBiotest Aktiengesellschaft Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Biotest Aktiengesellschaft.

Biotest Aktiengesellschaft Daily Commodity Channel Index (CCI) ChartBiotest Aktiengesellschaft Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Biotest Aktiengesellschaft.

Biotest Aktiengesellschaft Daily Chande Momentum Oscillator (CMO) ChartBiotest Aktiengesellschaft Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Biotest Aktiengesellschaft.

Biotest Aktiengesellschaft Daily Williams %R ChartBiotest Aktiengesellschaft Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Biotest Aktiengesellschaft.

Biotest Aktiengesellschaft Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Biotest Aktiengesellschaft.

Biotest Aktiengesellschaft Daily Average True Range (ATR) ChartBiotest Aktiengesellschaft Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Biotest Aktiengesellschaft.

Biotest Aktiengesellschaft Daily On-Balance Volume (OBV) ChartBiotest Aktiengesellschaft Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Biotest Aktiengesellschaft.

Biotest Aktiengesellschaft Daily Money Flow Index (MFI) ChartBiotest Aktiengesellschaft Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Biotest Aktiengesellschaft.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-21BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-08ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-04-28WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-15ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-26STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-17ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-24RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-26CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside

6.3. Candlestick Patterns

Biotest Aktiengesellschaft Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Biotest Aktiengesellschaft based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose43.400
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Biotest with someone you think should read this too:
  • Are you bullish or bearish on Biotest? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Biotest? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Biotest Aktiengesellschaft

I send you an email if I find something interesting about Biotest Aktiengesellschaft.


Comments

How you think about this?

Leave a comment

Stay informed about Biotest Aktiengesellschaft.

Receive notifications about Biotest Aktiengesellschaft in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.